(Based on BPI)
Cost pressures driven by stricter price controls and tighter reimbursement policies in Western Europe are restricting pharmaceutical research spending on the European continent. The bulk cost of clinical trials is related to patient compensation and has increasingly grown more expensive in Western Europe, and their compensation of volunteers and medical personnel is now similar to US rates. As the Eastern European CRO only bill for costs incurred above standard operating expenses. In addition with a sizable, homogenous populations with similar racial characteristics as the Western World, have facilitated patient recruitment drive. Eastern European studies have also been marked by high compliance with study protocols. Patients in that region tend to be relatively under-medicated, which reduces the risk that they will use competing medications and compromising the integrity of the final data. All in all they are getting more attractive and more clinical development is going to be there. Having said that, the entry barriers to Eastern Europe are relatively high, with many CROs have chosen to partner with established providers in the region rather than install their own facilities. Also linguistic and cultural similarities with US and qualified physician and proven quality of trial centers are likely to make Western Europe important in the market for outsourced clinical research.
So for Eastern Europe:
1. lower cost
2. sizable homogenous population similar to Western Europe
3. high compliance with study protocol
4. Result integrity with less complication of other medication
For Western Europe:
1. similar linguistic and cultural background
2. proven quality
文章定位：
